More importantly, a recombinant form of human SAP (PRM-151) has been proposed as a novel anti-fibrotic immunomodulator in IPF patients, based on phase 2 randomized and placebo-controlled trials, with no serious adverse reactions (75–77), which encourages clinical trials to evaluate the efficacy of this short pentraxin, in addition to PTX3, in the treatment of IA. This evidence concerns the gene PTX3 and idiopathic pulmonary fibrosis.